Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mattheos Bobos

Showing results (71-80 of 96) with videos related to

Pageof 10
Sort By:
Journal of Translational Medicine|May 30, 2015
Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation studyAngelos Koutras, Konstantine T Kalogeras, Ralph M Wirtz, et al.
Cancer Genomics & Proteomics|February 29, 2020
Tumor Mutational Patterns and Infiltrating Lymphocyte Density in Young and Elderly Patients With Breast CancerAdamantia Nikolaidi, Vassiliki Kotoula, Georgia-Angeliki Koliou, et al.
Cancer Chemotherapy and Pharmacology|May 8, 2015
PAI-1 and HER2 interaction in advanced breast cancer disease: evidence for added benefit from trastuzumab in HER2-negative patientsAnna Koumarianou, Georgia Karayannopoulou, Georgia Gourgioti, et al.
Cancer Research and Treatment|November 18, 2021
Clinical Significance of Major Angiogenesis-Related Effectors in Patients with Metastatic Breast Cancer Treated with Trastuzumab-Based RegimensHelen P Kourea, Foteinos-Ioannis Dimitrakopoulos, Georgia-Angeliki Koliou, et al.
Cancer Genomics & Proteomics|October 22, 2018
Evaluation of the Insulin-like Growth Factor Receptor Pathway in Patients with Advanced Breast Cancer Treated with TrastuzumabChristos Christodoulou, Georgios Oikonomopoulos, Georgia Angeliki Koliou, et al.
Clinical Breast Cancer|September 6, 2017
Correlation of MYC Gene and Protein Status With Breast Cancer Subtypes and Outcome of Patients Treated With Anthracycline-Based Adjuvant Chemotherapy. Pooled Analysis of 2 Hellenic Cooperative Group Phase III TrialsAnna Batistatou, Vassiliki Kotoula, Mattheos Bobos, et al.
Breast Cancer Research and Treatment|July 3, 2016
Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytesVassiliki Kotoula, Vasilios Karavasilis, Flora Zagouri, et al.
Oncotarget|October 28, 2015
Tumors with high-density tumor infiltrating lymphocytes constitute a favorable entity in breast cancer: a pooled analysis of four prospective adjuvant trialsVassiliki Kotoula, Kyriakos Chatzopoulos, Sotiris Lakis, et al.
Journal of Translational Medicine|January 14, 2012
HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapyGeorge Fountzilas, Christos Valavanis, Vassiliki Kotoula, et al.
Breast Cancer Research and Treatment|March 22, 2012
Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group StudyFlorentia Fostira, Marianthi Tsitlaidou, Christos Papadimitriou, et al.
Pageof 10

Showing results (71-80 of 96) with videos related to

Sort By:
Pageof 10
Journal of Translational Medicine|May 30, 2015
Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation studyAngelos Koutras, Konstantine T Kalogeras, Ralph M Wirtz, et al.
Cancer Genomics & Proteomics|February 29, 2020
Tumor Mutational Patterns and Infiltrating Lymphocyte Density in Young and Elderly Patients With Breast CancerAdamantia Nikolaidi, Vassiliki Kotoula, Georgia-Angeliki Koliou, et al.
Cancer Chemotherapy and Pharmacology|May 8, 2015
PAI-1 and HER2 interaction in advanced breast cancer disease: evidence for added benefit from trastuzumab in HER2-negative patientsAnna Koumarianou, Georgia Karayannopoulou, Georgia Gourgioti, et al.
Cancer Research and Treatment|November 18, 2021
Clinical Significance of Major Angiogenesis-Related Effectors in Patients with Metastatic Breast Cancer Treated with Trastuzumab-Based RegimensHelen P Kourea, Foteinos-Ioannis Dimitrakopoulos, Georgia-Angeliki Koliou, et al.
Cancer Genomics & Proteomics|October 22, 2018
Evaluation of the Insulin-like Growth Factor Receptor Pathway in Patients with Advanced Breast Cancer Treated with TrastuzumabChristos Christodoulou, Georgios Oikonomopoulos, Georgia Angeliki Koliou, et al.
Clinical Breast Cancer|September 6, 2017
Correlation of MYC Gene and Protein Status With Breast Cancer Subtypes and Outcome of Patients Treated With Anthracycline-Based Adjuvant Chemotherapy. Pooled Analysis of 2 Hellenic Cooperative Group Phase III TrialsAnna Batistatou, Vassiliki Kotoula, Mattheos Bobos, et al.
Breast Cancer Research and Treatment|July 3, 2016
Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytesVassiliki Kotoula, Vasilios Karavasilis, Flora Zagouri, et al.
Oncotarget|October 28, 2015
Tumors with high-density tumor infiltrating lymphocytes constitute a favorable entity in breast cancer: a pooled analysis of four prospective adjuvant trialsVassiliki Kotoula, Kyriakos Chatzopoulos, Sotiris Lakis, et al.
Journal of Translational Medicine|January 14, 2012
HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapyGeorge Fountzilas, Christos Valavanis, Vassiliki Kotoula, et al.
Breast Cancer Research and Treatment|March 22, 2012
Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group StudyFlorentia Fostira, Marianthi Tsitlaidou, Christos Papadimitriou, et al.
Pageof 10